Naphthazalin

Naphthazalin

SCHEMBL149279

O=C1C=CC(=O)c2c(O)ccc(O)c21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TXNRD1 Q16881 3/20 1.00
AURKA O14965 2/20 1.00
CDC25B P30305 2/20 1.00
AURKB Q96GD4 2/20 1.00
TXNRD3 Q86VQ6 2/20 1.00
TXNRD2 Q9NNW7 2/20 1.00
CYP1A1 P04798 1/20 1.00
CYP1A2 P05177 1/20 1.00
COPS5 Q92905 1/20 1.00
MAPT P10636 6/20 0.58
MEN1 O00255 5/20 0.58
KMT2A Q03164 5/20 0.58
ALDH1A1 P00352 5/20 0.58
MAPK1 P28482 5/20 0.58
HPGD P15428 5/20 0.58
USP2 O75604 4/20 0.58
THRB P10828 4/20 0.58
ALOX15 P16050 4/20 0.58
HSD17B10 Q99714 4/20 0.58
TP53 P04637 4/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Naphthazalin SCHEMBL29353283 1.00 TXNRD1 (1.00) TXNRD1AURKACDC25BAURKBTXNRD3
Naphthazalin SCHEMBL27700955 1.00 TXNRD1 (1.00) TXNRD1AURKACDC25BAURKBTXNRD3
Naphthazalin SCHEMBL6122890 0.97 TXNRD1 (0.94) TXNRD1AURKACDC25BAURKBTXNRD3
Naphthazalin SCHEMBL21403377 0.97 TXNRD1 (0.94) TXNRD1AURKACDC25BAURKBTXNRD3
SCHEMBL10401666 0.87 TXNRD1 (0.76) TXNRD1AURKACDC25BAURKBTXNRD3
SCHEMBL8996435 0.85 TXNRD1 (0.73) TXNRD1AURKACDC25BAURKBTXNRD3
SCHEMBL2182692 0.85 AURKA (0.73) TXNRD1AURKACDC25BAURKBTXNRD3
SCHEMBL17265619 0.85 AURKA (0.73) TXNRD1AURKACDC25BAURKBTXNRD3
SCHEMBL28091853 0.84 TXNRD1 (0.71) TXNRD1AURKACDC25BAURKBTXNRD3
SCHEMBL31157962 0.84 TXNRD1 (0.71) TXNRD1AURKACDC25BAURKBTXNRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125721-A1 ACIDOPHILIC FUSARIUM OXYSPORUM STRAINS, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE THE FYNDER GROUP, INC. 2026-05-07 US claimed
EP-4680027-A1 A METHOD FOR IMPARTING ANTIMICROBIAL PROPERTIES TO A SYNTHETIC SUBSTRATE Biocompatibility Innovation Srl (IT) 2026-01-21 EP claimed
EP-3788093-B1 SQUARIC ACID-BASED POLYMERS, THEIR MANUFACTURING PROCESSES AND THEIR USES HYDRO QUEBEC (CA) 2025-12-10 EP claimed
CN-120114610-A Copper ion complex based on protein template and preparation method and application thereof 中国药科大学 2025-06-10 CN claimed
US-20250129207-A1 SQUARIC ACID-BASED POLYMERS, THEIR MANUFACTURING PROCESSES AND THEIR USES HYDRO-QUéBEC (CA) 2025-04-24 US claimed
US-12111315-B2 Smart glass slide for microarrays ROBERT BOSCH GMBH (DE) 2024-10-08 US claimed
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 US claimed
WO-2024189407-A1 A METHOD FOR IMPARTING ANTIMICROBIAL PROPERTIES TO A SYNTHETIC SUBSTRATE Biocompatibility Innovation S.r.l. (IT) 2024-09-19 WO claimed
EP-3280402-B1 TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING BIOMENDICS LLC (US) 2024-06-05 EP claimed
CN-118022683-A Preparation method of adsorbent, MAA wastewater treatment device and process 万华化学集团股份有限公司 2024-05-14 CN claimed
US-4832943-A HYDROXYQUINONE, MESOTARTARALDEHYDE L'OREAL (FR) 1989-05-23 US claimed
EP-0109677-B1 DIPLATINUM COMPLEX, METHOD FOR PREPARING AND AN ANTI-CANCER AGENT CONTAINING SAME Research Corporation (US) 1987-07-22 EP claimed
US-4650885-A Process for preparing derivatives of naphthazarin NIPPON OIL CO., LTD. (JP) 1987-03-17 US claimed
EP-0200219-A2 Process for preparing derivatives of naphthazarin NIPPON OIL CO. LTD. (JP) 1986-11-05 EP claimed
US-4588831-A ANTITUMOR AGENTS NATEC (DE) 1986-05-13 US claimed
EP-0144809-A2 Complex platinum compounds of substituted 5,8-dihydroxy-1,4 naphtoquinones, process for their preparation and their use NATEC Institut für naturwissenschaftlich- technische Dienste GmbH (DE) 1985-06-19 EP claimed
US-4425404-A MULTILAYER, PROTECTIVE COATINGS MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) 1984-01-10 US claimed
US-4078070-A DIHYDROPYRAN-3-CARBOXYLIC ACID ANILIDE WITH A BENZIMIDAZOLE-2-CARBAMATE HOECHST AKTIENGESELLSCHAFT (DT) 1978-03-07 US claimed
US-4041164-A ALUMINUM CHELATES OF A HYDROXY-QUINONE HOECHST AKTIENGESELLSCHAFT (DT) 1977-08-09 US claimed
US-4030882-A Solvent dyeing compositions and a method of dyeing polyester fibers therewith EASTMAN KODAK COMPANY (US) 1977-06-21 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125721-A1 ACIDOPHILIC FUSARIUM OXYSPORUM STRAINS, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE TKT, SPOUT1, TALDO1 TXNRD1 182/4885AURKA 2442/4885CDC25B 3264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.